AKT1 and hepatocellular carcinoma: Specifically, if we are able to target the upstream pathways involved in HCC tumour progression (i.e., Wnt/β‐catenin, PI3K/Akt or MAPK) involved in cell proliferation and survival, we can discourage cancer growth and metastasis.